Plus Therapeutics announced that its Cnside® cerebrospinal fluid detection assay is now officially covered by Blue Shield of California insurance, with the test primarily used for the diagnosis of metastatic central nervous system cancers.

This groundbreaking advancement means that eligible insured patients will be able to receive insurance reimbursement when undergoing relevant tests, significantly reducing their medical burden. Cnside®, as an innovative cerebrospinal fluid detection tool, provides important support for the precise diagnosis of metastatic central nervous system cancer by analyzing biomarkers in the cerebrospinal fluid. Obtaining coverage approval from Blue Shield of California not only demonstrates the clinical value of this testing technology but will also further promote its broader application in medical practice. For Plus Therapeutics, this milestone event marks substantial progress in the commercialization of the company's products. As insurance coverage expands, more patients will have the opportunity to benefit from this cutting-edge testing technology, which will also help enhance the company's market competitiveness in the field of tumor diagnosis.